Etelcalcetide Brand Name– Parsabiv
What is Etelcalcetide
Etelcalcetide is an intravenous, calcimimetic and calcium-sensing receptor (CaSR) agonist indicated for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
Etelcalcetide is administered 3 times weekly at the end of hemodialysis sessions.
Etelcalcetide lowers serum calcium which may lead to serious, life-threatening hypocalcemia associated with seizures, QT prolongation, and ventricular arrhythmias.
Ensure corrected serum calcium is at or above the lower limit of normal before starting etelcalcetide therapy, and monitor corrected serum calcium throughout treatment.
Etelcalcetide has not been studied in patients with parathyroid carcinoma, primary hyperparathyroidism, or chronic kidney disease not on hemodialysis and is not recommended for use in these patients.
Etelcalcetide was FDA-approved in February 2017.
Indications
- hyperparathyroidism
For the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis
Side Effects
- antibody formation
- diarrhea
- edema
- GI bleeding
- headache
- heart failure
- hypocalcemia
- hypoesthesia
- hypophosphatemia
- muscle cramps
- myalgia
- nausea
- osteodystrophy
- paresthesias
- pruritus
- QT prolongation
- rash
- seizures
- urticaria
- vomiting
Monitoring Parameters
- serum calcium
- serum intact parathyroid hormone concentrations (iPTH)
Contraindications
- breast-feeding
- esophagitis
- gastritis
- GI bleeding
- heart failure
- hypocalcemia
- long QT syndrome
- peptic ulcer disease
- pregnancy
- QT prolongation
- seizure disorder
- vomiting
Interactions
- Cinacalcet
- Denosumab
